Market Place
Sourcing Support
Endeavor BioMedicines Doses 1st Patient in Ph 2b WHISTLE-PF Trial
20 Nov 2024 //
BUSINESSWIRE
Endeavor BioMedicines Appoints Bill Bradford, M.D., Ph.D., to Board of Directors
12 Sep 2024 //
BUSINESSWIRE
Endeavor links IPF drug to improved lung function in phase 2
20 May 2024 //
FIERCE BIOTECH
ENV-101 Phase 2a Shows Lung Function, Fibrosis Reversal In IPF
19 May 2024 //
BUSINESSWIRE
Endeavor: ENV-101 Phase 2a Data At ATS 2024
01 May 2024 //
BUSINESSWIRE
Endeavor raises $132.5m for fibrosis, cancer drugs
24 Apr 2024 //
PHARMAPHORUM
Endeavor Appoints Chris Krueger As Chief Operating Officer
16 Apr 2024 //
BUSINESSWIRE
Endeavor BioMedicines Appoints Enoch Kariuki, Pharm.D. as President
14 Mar 2024 //
BUSINESSWIRE
Endeavor BioMedicines Successfully Completes Phase 2a Trial of ENV-101
24 Jan 2024 //
BUSINESSWIRE
Endeavor BioMedicines Appoints Enoch Kariuki, Pharm.D. to Board of Directors
19 Dec 2023 //
BUSINESSWIRE
Endeavor signs $430M deal for Hummingbird’s HER3-targeted ADC
20 Oct 2023 //
FIERCE BIOTECH
Endeavor BioMedicines Completes Enrollment in Phase 2a Clinical Trial of ENV-101
06 Sep 2023 //
BUSINESSWIRE
Endeavor BioMedicines Partners with xCures for PII Trial of ENV-101 (taladegib)
31 May 2022 //
BUSINESSWIRE
Endeavor Doses First Patient in Phase 2 Oncology Study of ENV-101 (Taladegib)
25 May 2022 //
BUSINESSWIRE
Endeavor raises $101m in Series B round to progress treatment pipeline
08 Feb 2022 //
PHARMACEUTICAL-TECHNOLOGY
Endeavor Bio Closes $101M Series B Financing for Precision Medicine Pipeline
07 Feb 2022 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.